Concourse Financial Group Securities, Inc. Monte Rosa Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$3.59 - $6.97 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$3.38 - $7.86 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$4.26 - $8.46 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$2.5 - $5.93 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$4.78 - $7.22 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$4.78 - $7.22 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.53 - $8.4 $0 - $0
Q1 2023 May 15, 2023	BUY	$5.95 - $8.21 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$6.71 - $9.72 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$7.17 - $12.16 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$6.15 - $14.99 $0 - $0
Q1 2022 May 09, 2022	BUY	$10.36 - $20.41 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$16.28 - $27.15 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$18.59 - $42.21 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$18.86 - $22.7 $0 - $0

Others Institutions Holding GLUE

# of Institutions

Shares Held

43.9M

Call Options Held

141K

Put Options Held

31.2K

Nea Management Company, LLC Timonium, MD

7.69M
Shares

$65.3 Million
3.11% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.6M
Shares

$56 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

5.79M
Shares

$49.2 Million
0.46% of portfolio
Baker Bros. Advisors LP New York, NY

4.92M
Shares

$41.7 Million
0.28% of portfolio
Suvretta Capital Management, LLC New York, NY

2.66M
Shares

$22.6 Million
0.55% of portfolio

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $397M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account